Population-based estimation of the prevalence of Parkinson disease in Germany
- Parkinson’s Disease is the second most common neurodegenerative disorder worldwide. Motor and non-motor symptoms are developing with increasing duration of disease. The main therapy of patients with Parkinson’s Disease are dopaminergic drugs. However, this treatment is often insufficient to control for the symptoms in the late stages of the disease. Alternative forms of treatment are available. The Department of Neurology, University of Marburg conducted a study to describe patients in the late stages of the disease with respect to symptoms and forms of treatment. One aim of this study was the estimation of the number of patients that are eligible for the different forms of treatment in the late stages of the disease. For this estimation reliable epidemiological figures of Parkinson’s Disease, i.e. prevalence, stages of disease severity and duration of the disease, are needed. However, information on prevalence could only be extracted from published non-German studies and the stages of disease severity and the duration of the disease was only assessed in German convenience samples.
The BIPS thus conducted a study, in which age- and gender-specific prevalences of Parkinson's Disease were estimated by means of a meta-analysis. These estimates were then used to standardize the distribution of disease stage and duration in the convenience samples. The study could thus provide up-to-date age- and gender-specific as well as severity base prevalence figures. Nevertheless, high-quality studies to estimate population-based figures of disease severity are still recommended.
- Begin: October 2012
End: December 2012
- TransMIT Society for Technology Transfer GmbH, TransMIT-Center for Therapeutic Research for Neurological Diseases
- PD Dr. rer. nat. Oliver Riedel
- Prof. Dr. Richard Dodel (Klinik für Neurologie, Philipps-Universität, Marburg)